Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BEAMED could be the next generation of Intuitive Surgical (ISRG)!
gh
I see the BeaMed platform as a step forward in micro laser surgery. The epilepsy treatment is only the beginning. Surgery in joints, lungs, the gut, the heart, etc. can all be improved and these 2 tech wizards from Israel have a proven record of success!
This investment by Leo can give us the means to move forward on Brilacidin without having to cut big pharma in for the lion's share of B's potential $$$.
gh
If I worked at the B U Bioweapons lab, I'd want B nasal spray and B as a nebulizer. The virus kills when the lungs are overcome.
gh
Just imagine, preventing the common cold, etc. for 4 cents a share!
gh
NEWS:
New In Vitro Data Supporting the Broad-Spectrum Antiviral Activity of Innovation Pharmaceuticals’ Brilacidin Presented at 2022 Military Health System Research Symposium
Brilacidin shown to inhibit multiple alphaviruses, the bunyavirus Rift Valley Rift Fever, and Echovirus (a non-enveloped picornavirus)
WAKEFIELD, MA / September 15, 2022 Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that new Brilacidin antiviral data, based on research conducted by scientists at George Mason University’s Center for Infectious Disease Research (formerly NCBID), was presented at the 2022 Military Health System Research Symposium (MHSRS), held this week at the Gaylord Palms Resort and Convention Center, Kissimmee, FL. The corresponding scientific poster is available on the Company’s website at the link below.
“Brilacidin, a Host Defense Peptide Mimetic, is a Broad-Spectrum Countermeasure Strategy Against Acutely Infectious Viruses.” Poster Presentation. 2022 Military Health System Research Symposium.
www.ipharminc.com/s/MHSRS2022-Brilacidin-poster-fv.pdf
Across multiple cell lines and under different testing conditions, research showed Brilacidin inhibited viral replication in a statistically significant manner in encephalitic alphaviruses, including Venezuelan Equine Encephalitis Virus (VEEV), Eastern Equine Encephalitis Virus (EEEV), and Sindbis Virus (SINV). Brilacidin also was shown to inhibit Rift Valley Fever Virus (RVRF), a contagious bunyavirus that can lead to blindness, liver failure, and hemorrhagic fever in infected individuals. Moreover, anti-inflammatory activity was observed, indicating intracellular events are modulated by Brilacidin treatment. Brilacidin is thus able to exert a combined protective effect by decreasing viral and inflammatory load.
The in vitro evaluation of Brilacidin’s antiviral activity was expanded to Echovirus, a non-enveloped picornavirus, to assess Brilacidin’s effect on early viral entry in contrast to its ability to disrupt the lipid membranes of enveloped viruses. Brilacidin was shown to inhibit Echovirus, suggesting Brilacidin possesses additional antiviral mechanisms beyond its ability to directly impact viral envelopes.
Collectively, these data support Brilacidin’s potential to be developed as a broad-spectrum antiviral.
Beyond research presented at the MHSRS, Brilacidin is being studied by NIH/NIAID-affiliated researchers in different viruses. Findings from this research, as well as results from the Company’s Phase 2 clinical trial of intravenous Brilacidin in hospitalized cases of moderate-to-severe COVID-19 (NCT04784897) -- which showed beneficial treatment effects -- are being prepared for publication. Three years into the COVID-19 pandemic, followed by a worldwide monkeypox outbreak, it is clear effective broad-spectrum antiviral prevention and treatment strategies are needed.
Here is an opportunity for us to spread the word about BRILACIDIN to a worldwide audience: https://inb.who.int/home/public-hearings/second-round
gh
I agree, Attila, Brilacidin is a game changer. Let no one convince you otherwise.
I've said it many times here and elsewhere, "Brilacidin is the Penicillin of the 21st Century"
gh
My current opinion of IPIX:
I have been invested here for many years and look at my paper loss as a sunk cost.
My hope is that the current stake in Squalus will generate income in time to realize the true value of Kevetrin and Brilacidin, two nuggets sitting on our shelf that are unrecognized by the market.
gh
Me too. Eleven years; why quit now?
gh
I'm not a doc or scientist, just an interested investor. My take on the B-Covid trial is that B did not heal lungs and other already severely damaged organs; too bad. The trial did NOT show that B was ineffective in killing the virus. I find it harder and harder to resist buying more at these bargain prices. Thanks to Leo, the company will not be forced into bankruptcy.
I've said it before "BRILACIDIN is the penicillin of the 21st century"
gh
If Kips Bay is buying it would be an even better sign. :)
gh
I agree with your post completely and have added recently at $.068. I too have faith in Brilacidin, Kevetrin, and Leo. The disappointing trial results are a setback that will make the ultimate success all the sweeter.
gh
Great perspective IrishGuy.
With 50 Million shares traded by 10:15 today, just think of all the naked short shares covered. A year from now, those selling now will be kicking themselves in the butt.
I'm buying today!
gh
Why would anyone with any knowledge of Brilacidin, or Kevetrin sell at these prices?
I'm looking for an entry point.
gh
The MMs and flippers have given us yet another (maybe the last) buying opportunity at a huge discount from Thursday's high price. Once the news hits, the sky is the limit!
GLTA longs
gh
What about the CCP?
gh
I posted;
"With a successful BRILACIDIN trial being reported soon, IPIX will become a healthy, valuable company. We will have the financial resources to fund the next phases of trials of KEVETRIN, LEADING TO GREAT SUCCESS in the long term. imho
I'm not selling out for peanuts!
Know what you own."
You asked me to define 'peanuts'.
Peanuts would be a subjective number for each investor; for me, given the fraudulent and/or nefarious activity IPIX has endured, I consider $10 a reasonable price. Less than that to be 'peanuts'. Obviously, if you've only been invested for a couple of months with an average cost of $.20, a one-dollar buyout would seem like a great windfall.
Good luck to all true INVESTORS on IPIX.
gh
Here Today,
I too first invested here because of KEVETRIN; my first purchase was for exactly One Dollar. There had been an enthusiastic article in the NY Times about trials at Harvard and the P-53 gene.
The price kept rising to nearly $5 and I was a genius.
Lots of FUDsters and fraudsters and Market Manipulators have held us back, but now it seems that might all be behind us and we may have the funds to take KEVETRIN off the back burner and have a real shot for a second home run. If only we get the first homer with BRILACIDIN.
gh
Flonase for hay fever; BRILACIDIN for viral and bacterial infection! Maybe B for all.
gh
I have no source for my impression that BRILACIDIN is relatively cheap and easy to produce. I wonder what information has been posted (if any) with regard to B's cost of production.
gh
XOC
Your post is why I hope for other than an outright sale of the entire company (except if the price would be so high that it would include all possible future appreciation of IPIX). I don't believe any Big Pharma can afford to meet my estimate of IPIX's value going forward.
The bidding war will start soon. Maybe it already has. :)
gh
Why would Brilacidin be listed on the VAERS list? It's not a vaccine.
gh
MinnieM,
You posted, "If Brialacidin ph2 covid trial has good results the company will end up partnered or sold. My preference would be to see a complete sale."
I would agree but I worry that the price would not reflect the true value of the company due to the depressed market price. If, after good news, a short squeeze, and a significant premium, that would be great. Lowball offers should be rejected. Let's have a bidding war!
My dream deal would be $25 cash plus $25 worth of the purchaser's stock. That way we could bask in the glow of B's and K's future development.
I can dream, can't I?
gh
I fear the bureaucrats and big Pharma will stymie IPIX here in the home stretch and block or delay our medical and financial success.
After our successful (fingers crossed) Phase 2 trial results, when the fix is in, blocking us here, I expect a foreign country to approve BRILACIDIN for emergency use. Russia, India, Japan, and/or Brazil come to mind. When proven safe and effective in the real world, production and use become widespread, its availability, even here in the US will become inevitable despite the evil efforts of our opponents.
gh
Rocky, you posted: "Due to the presence of the virus the body will still do its job learning how to kill the virus in tandem to Brilacidin killing what it can find. As GMU continues to study it, I wouldn’t be surprised to find out that it annihilated shingles while it was doing in corona. That would set me laughing."
There's a list a mile long that B might affect in addition to corona.
How many viral, bacterial and fungal maladies are there?
And we have K for cancer, once we have the $$$ for trials!
I'm very optimistic.
gh
Is the military allowed to buy a drug that is not approved by FDA?
Would that purchase be public information?
Just asking.
gh
With regard to my post yesterday,
"I just spoke with TDAmeritrade and Schwab about inaccurate info showing on their IPIX summary pages. Neither shows the institutional ownership of Kips Bay as shown on the SEC 13G/A April 19, 2021 filing. TDA shows .02%; Schwab 0%. The filing shows 4.97%
This is information that any potential new investor would find doing their due diligence when considering IPIX. How many investors have NOT bought IPIX because of this "mistake"?
***Please check your broker's webpage for this data and request(demand) that current stats be provided.***"
gh
I got a phone call from Schwab this morning; since Kips Bay is a private entity, it does not fit the definition of 'institution' and so their published data is correct.
My mistake.
gh
Shazamm, They both said that they would kick it up the line; they were not empowered to actually make the change. I plan to call back daily with escalating ardor until the change is made. It borders on institutional incompetence for this to occur. If this goes on without correction, it may be corruption.
gh
I just spoke with TDAmeritrade and Schwab about inaccurate info showing on their IPIX summary pages. Neither shows the institutional ownership of Kips Bay as shown on the SEC 13G/A April 19, 2021 filing. TDA shows .02%; Schwab 0%. The filing shows 4.97%
This is information that any potential new investor would find doing their due diligence when considering IPIX. How many investors have NOT bought IPIX because of this "mistake"?
***Please check your broker's webpage for this data and request(demand) that current stats be provided.***
gh
I have emailed Mr. Seifert and another reporter at the Boston Business Journal a dozen or so times over the years. He seems politely interested but will wait for clinical trial results before publishing any Covid Brilacidin story.
gh
If we get a positive result from the current trial and FDA drags it's feet on an EUA approval, what would stop India, Brazil or any other country from their own EUA? This would circumvent the red tape factory in Washington D.C.
gh
Since BRILACIDIN treats c-19 and all these other viruses, what are the odds that it would NOT treat the c-19 variants?
Miniscule, I'd wager.
gh
I agree with your optimistic assessment of BRILACIDIN. I've said many times, "BRILACIDIN is the Penicillin of the 21st Century".
gh
Forgive my 73-year-old memory; are both the upcoming presentations, later this month and in August, going to be available online?
gh
After BRILACIDIN is approved, the demand for vaccines will drop if we can produce enough.
gh
With good news in a few short weeks, BRILACIDIN and the long-suffering shareholders will be vindicated. The scourages of viral and other infections and cancer will fade into history. Dr. Menon, Dr. DeGrado, and Leo will be revered as the scientific and business geniuses who manipulated molecules and dollars in the great American Capitalist system to effect this miraculous achievement.
Happy INDEPENDENCE DAY!
gh
MinnieM, You are a fount of due diligence and wisdom; a treasure for this board and for IPIX.
thanks,
gh
It is always nice to hear from You MinnieM. Your long-term outlook and moderate posts encourage me to keep buying when funds are available. God Bless You.
gh
I'd think Dr. DeGrado would be a worthy candidate to shepherd his miracle drug onward if Leo steps down.
gh
Just daydreaming here:
What would happen if India or Brazil or any country reviewed the current literature and trial stats and decided to approve Brialcidin for emergency use and ordered a million doses?
gh